Ubiquitin System: The Next Class of Drug Targets?
A Complex Role in Cellular Process & Growing Tool Set to Elucidate It
Bispecific Antibodies Close in on Cancer
Plotting Molecular Pincer Movements, Denying Cancer Room to Maneuver
Resolving Nonspecific Binding, Regeneration and Other Problems
Molecular Diagnostic Reimbursement
Companies are facing significant challenges in gaining provider acceptance and reimbursement for molecular diagnostics, which are the hallmark of personalized medicine. Steven Burrill, CEO of Burrill & Company, even likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.” Some companies are prevailing, however, through strategies that include obtaining a dedicated current procedural terminology (CPT) code, gaining acceptance of diagnostics as a standard of care, and forming partnerships with the pharmaceutical industry. Others are concentrating efforts on developing diagnostics for the ex-U.S. market. How is your company handling this issue?